World Journal of Analytical Chemistry
ISSN (Print): 2333-1178 ISSN (Online): 2333-1283 Website: Editor-in-chief: Raluca-Ioana Stefan-van Staden
Open Access
Journal Browser
World Journal of Analytical Chemistry. 2013, 1(1), 1-7
DOI: 10.12691/wjac-1-1-1
Open AccessArticle

Estimation of Centrally Acting Muscle Relaxant Drug Tolperisone Hydrochloride Using HPTLC Method

Usmangani K. Chhalotiya1, , Kashyap K. Bhatt1, Dimal A. Shah1, Dhruti C. Nagda2 and Gautam R. Chauhan3

1Indukaka Ipcowala College of Pharmacy, Beyond GIDC, Gujarat, India

2A. R & G. H. Patel Institute of Pharmacy, Gujarat, India

3Sophisticated Instrumentation Centre for Applied Research and Testing, Gujarat, India

Pub. Date: February 28, 2013

Cite this paper:
Usmangani K. Chhalotiya, Kashyap K. Bhatt, Dimal A. Shah, Dhruti C. Nagda and Gautam R. Chauhan. Estimation of Centrally Acting Muscle Relaxant Drug Tolperisone Hydrochloride Using HPTLC Method. World Journal of Analytical Chemistry. 2013; 1(1):1-7. doi: 10.12691/wjac-1-1-1


A sensitive, selective and precise high performance thin layer chromatographic method has been developed and validated for the determination of tolperisone hydrochloride in bulk drug and in formulation. The method employed HPTLC aluminium plates pre-coated with silica gel 60F-254 as the stationary phase while the solvent system was methanol: ethyl acetate (3:7, v/v). The Rf value of tolperisone hydrochloride was observed to be 0.50 ± 0.008. The densitometric analysis was carried out in absorbance mode at 261nm. The linear regression analysis data for the calibration plots showed a good linear relationship for tolperisone hydrochloride over a concentration range of 50 - 800 ng/spot. The limit of detection and limit of quantification for tolperisone hydrochloride was found to be 7.57 and 10ng/spot. Tolperisone hydrochloride was subjected to acid and alkali hydrolysis, chemical oxidation, wet hydrolysis, dry heat degradation and sun light degradation. The degraded product peaks were well resolved from the pure drug peak with significant difference in their Rf values. Stressed samples were assayed using developed HPTLC method. The proposed method was validated with respect to linearity, accuracy, precision and robustness. The method was successfully applied to the estimation of tolperisone in tablet dosage forms. The proposed study describes a HPTLC method for the estimation of tolperisone in bulk and their pharmaceutical dosage form. Statistical analysis showed that the method is suitable for the routine analysis of tolperisone in tablets.

Tolperisone hydrochloride; forced degradation; HPTLC; validation

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 8


[1]  Porszasz, J., Barankay, T., Nador, K., Gibiszer, K., “Pharmakologie einer neuen interneuron-lahmenden substanz 1-piperidino-2- methyl-3-(p-tolyl)-propan-3-on” Arzneim-Forsch Drug Research, 11: 257-260. 1961.
[2]  The Pharmacopoeia of Japan, Ministry of Health, Labour and Walfare, Prefectural office in Japan, 11th ed., 2. 1027. 1986.
[3]  The Pharmacopoeia of Japan, Ministry of Health, Labour and Walfare, Prefectural office in Japan, 12th ed., 554. 1991.
[4]  Jagathi, V., “Assay of tolperisone by extractive Spectrophotometry” Research Journal of Pharmaceutical, Biological and Chemical Sciences, 1(3): 654. 2010.
[5]  Sai, P. P., Anupama, B., Rao G. D., “Spectrophotometric determination of Tolperisone using 2, 4-dinitrophenylhydrazine reagent” International Journal of Research in Pharmaceutical Science, 1(3). 317-320. 2010.
[6]  Orgovan, G., Tihanyi, K., Noszal B., “NMR analysis, protonation equilibria and decomposition kinetics of Tolperisone” Journal of Pharmaceutical and Biomedical Analysis, 50: 718-723. 2009.
[7]  Sae-Lee, N., Sae-Lee, N., “Effects of temperature and humidity on stability of tolperisone hydrochloride” Southern Wesleyan University Journal of Pharmaceutical Sciences, 10: 121-124. 2005.
[8]  Sae-Lee, N., Sae-Lee, N., “The effect of temperature on stability of tolperisone hydrochloride solution” Thai pharmaceutical and health science journal, 11: 1-4. 2006.
[9]  Liawruangrath, S., Liawruangrath, B., “High performance thin layer chromatographic determination of tolperisone hydrochloride” Journal of Pharmeutical and Biomedical Analysis, 20: 401-404. 1999.
[10]  Patel, M. J., Patel, A. N., Patel, C. N., Badmanaban, R. “A simple and sensitive HPTLC method for simultaneous analysis of tolperisone hydrochloride and etodolac in combined fixed-dose oral solid formulation” Journal of Planar Chromatography - Modern TLC, 25(1): 85-88. 2012.
[11]  Hubicka, U., Krzek, J., Zuromska – Witek, B. “TLC-densitometric determination of tolperisone and its impurities 4-methylpropiophenone and piperidine in pharmaceutical preparations” Journal of Liquid Chromatography and Related Technologies, 35(10): 1325-1335, 2012.
[12]  Liawruangrath, S., Liawruangrath, B., Pibool, P., “Simultaneous determination of tolperisone and lidocaine by high performance liquid chromatography” Journal of Pharmeutical and Biomedical Analysis, 26: 865-872. 2001.
[13]  Murali, M., Satyanarayana, P. V. V. “Simple validated isocratic RP -HPLC method for estimation of Tolperisone in bulk and pharmaceutical dosage form” Der Pharma Chemica, 3(5): 13-19. 2011.
[14]  Bae, J.W., Park, Y.S., Sohn, U.D., Myung, C.S., Ryu, B.K., Jang, C.G., Lee, S.Y. “HPLC determination of Tolperisone in human plasma” Archives of Pharmacal Research, 29: 339-342. 2006.
[15]  Yokoyama, T., Fukuda, K., Mori, S., Ogawa, M., Nagasawa, K. “Determination of tolperisone enantiomers in plasma and their disposition in rats” Chemical & Pharmaceutical Bulletin, 40(1): 272-274. 1992.
[16]  Carolin, N. I., Balan, P., Chiranjeevi N., Uma V. M., Karthikeyan M. “Method development, validation and forced degradation studies of tolperisone hydrochloride by RP-HPLC method in bulk and tablet dosage form” International Journal of Pharma and Bio Sciences, 2(4): 587-595. 2011.
[17]  International Conference on Harmonization (ICH); Validation of Analytical Procedures: Methodology (Q2R1); Food and Drug Administration, USA, 2005.